AUTHORS
Jiaxin Zheng, Fen Zhou, MD, PhD2, Feifei Tang, MD, PhD3, Zhixiang Wang4, Bailin He5, Wenhao Zhong6, Ye Jieyu7, Heng Mei, MD, PhD8, Hongsheng Zhou9
AFFILIATIONS
1 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
2 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Peking University People’s Hospital, Beijing, China
4 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
5 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
6 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
7 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
8 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
9 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
ABSTRACT
Background: IKZF1 deletion is a high-risk genetic feature in B-cell acute lymphoblastic leukemia (B-ALL) associated with poor survival. Inotuzumab ozogamicin (InO) has demonstrated efficacy in relapsed/refractory (R/R) B-ALL. However, real-world evidence regarding whether InO can overcome the adverse prognosis conferred by IKZF1 deletion remains limited.
Methods: This multicenter retrospective study included B-ALL patients treated with InO between June 2022 and September 2025. The safety cohort comprised 109 patients who received ≥1 dose. The efficacy cohort (n=82) included patients with known IKZF1 status (27 deleted, 55 wild-type), excluding those with mixed-phenotype acute leukemia and those treated with InO as induction/consolidation therapy.Patients were stratified as R/R (n=46), MRD-positive (n=15), or extramedullary disease (EMD, n=21). Outcomes included CR/CRi, MRD negativity, overall survival (OS), and progression-free survival (PFS).
Results: In the overall efficacy cohort, the median age was 34 years (range, 13–70). The CR/CRi rate was 81.5% (22/27) in the IKZF1 deletion group and 65.5% (36/55) in the wild-type group (P=0.197). With a median follow-up of 20.9 months,(95% CI:12.67–20.87months), the 2-year PFS was 53.5% versus 39.4% (P=0.302), and the 2-year OS was 82.5% versus 76.1% (P=0.876) for IKZF1 deletion versus wild-type, respectively.In the R/R subgroup, the CR/CRi rate was 80.0% (12/15) in the IKZF1 deletion group versus 80.6% (25/31) in the wild-type group. The median OS was not reached in either group. The median PFS was 13.9 months (95% CI: 2.3 months–not reached) in the IKZF1 deletion group versus 16.7 months (95% CI: 4.9 months–not reached) in the wild-type group (P=0.830). Univariate analysis revealed no significant association between IKZF1 deletion and OS (HR=1.77, 95% CI: 0.47–6.63, P=0.399) or PFS (HR=1.10, 95% CI: 0.47–2.57, P=0.826).In the MRD-positive subgroup , InO induced MRD negativity in 66.7% (6/9) of IKZF1 deletion patients and 50.0% (3/6) of wild-type patients. The 1-year PFS was 88.9% (8/9) versus 50.0% (3/6), respectively.In the EMD subgroup, although the small number of IKZF1 deletion cases (n=3) precluded statistical comparison, 1 patients achieved complete remission and 2 achieved partial EMD response.A total of 21 patients (7 with IKZF1 deletion, 14 wild-type) successfully received bridging therapy (12 to allogeneic hematopoietic stem cell transplantation, 9 to chimeric antigen receptor T-cell therapy). The bridging rate was comparable between the IKZF1 deletion (25.9%) and wild-type (25.5%) groups.Patients who underwent bridging in the IKZF1 deletion group had favorable 2-year PFS compared with the wild-type group (85.7% vs. 53.6%, P=0.23).In the safety cohort (N=109), the incidence of sinusoidal obstruction syndrome (SOS/VOD) was 2.8% (n=3). No treatment-related deaths occurred.
Conclusion: In this real-world cohort, InO demonstrated robust efficacy in IKZF1-deleted B-ALL, achieving CR and deep MRD negativity rates comparable to those in wild-type patients. InO effectively served as a bridge to HSCT or CAR-T, enabling high-risk IKZF1 deletion patients to access curative-intent therapies. These findings suggest that InO may overcome the adverse prognosis associated with IKZF1 deletion.
DISCLOSURES
Fen Zhou, MD, PhD: No relevant conflicts of interest to declare.